BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$30.9B
| $68.2M | 1.1% |
1,017,038
-251,649
| -20% | -$16.9M |
|
27
Arvinas
ARVN
$580M
| $58.8M | 0.95% |
2,386,600
-4,200
| -0.2% | -$103K |
|
28
Penumbra
PEN
$10.5B
| $53M | 0.86% |
272,683
-9,366
| -3% | -$1.82M |
|
29
Relay Therapeutics
RLAY
$709M
| $52.2M | 0.85% |
7,377,184
+1,000,069
| +16% | +$7.08M |
|
30
Option Care Health
OPCH
$4.7B
| $51.8M | 0.84% |
1,654,878
+237,999
| +17% | +$7.45M |
|
31
GE HealthCare
GEHC
$33B
| $49.9M | 0.81% |
531,967
+10,950
| +2% | +$1.03M |
|
32
Procept Biorobotics
PRCT
$2.11B
| $49.1M | 0.8% |
612,691
-56,358
| -8% | -$4.52M |
|
33
ESSA Pharma
EPIX
$11.2M
| $47.8M | 0.77% |
7,879,583
-10,000
| -0.1% | -$60.6K |
|
34
Zimmer Biomet
ZBH
$20.8B
| $46.7M | 0.76% |
432,805
-16,276
| -4% | -$1.76M |
|
35
HCA Healthcare
HCA
$95.4B
| $46.5M | 0.75% |
114,525
-7,779
| -6% | -$3.16M |
|
36
Elevance Health
ELV
$72.4B
| $46.5M | 0.75% |
89,328
-12,221
| -12% | -$6.35M |
|
37
Idexx Laboratories
IDXX
$50.7B
| $46.1M | 0.75% |
91,279
-2,079
| -2% | -$1.05M |
|
38
Cooper Companies
COO
$13.3B
| $43.8M | 0.71% |
397,373
| – | – |
|
39
Sarepta Therapeutics
SRPT
$1.98B
| $43M | 0.7% |
344,348
+92,027
| +36% | +$11.5M |
|
40
Exelixis
EXEL
$9.95B
| $41.5M | 0.67% |
1,600,000
-203,200
| -11% | -$5.27M |
|
|
41
Inspire Medical Systems
INSP
$2.53B
| $41.2M | 0.67% |
195,080
+70,356
| +56% | +$14.8M |
|
42
Cigna
CI
$80.2B
| $41M | 0.66% |
118,407
-4,683
| -4% | -$1.62M |
|
43
Eli Lilly
LLY
$661B
| $39.2M | 0.64% |
44,246
-5,428
| -11% | -$4.81M |
|
44
ResMed
RMD
$39.4B
| $39.1M | 0.63% |
160,128
+4,247
| +3% | +$1.04M |
|
|
45
Insmed
INSM
$30.3B
| $38.4M | 0.62% |
525,434
-496,266
| -49% | -$36.2M |
|
46
Edgewise Therapeutics
EWTX
$1.54B
| $38.1M | 0.62% |
1,428,929
| – | – |
|
47
Immunocore
IMCR
$1.78B
| $37.5M | 0.61% |
1,205,464
+50,810
| +4% | +$1.58M |
|
48
Beam Therapeutics
BEAM
$1.9B
| $37.2M | 0.6% |
1,518,121
+100,000
| +7% | +$2.45M |
|
49
Black Diamond Therapeutics
BDTX
$164M
| $37.1M | 0.6% |
8,517,839
| – | – |
|
50
Align Technology
ALGN
$9.59B
| $36.6M | 0.59% |
143,996
+14
| +0% | +$3.56K |
|